Vera Therapeutics - October 22 Investor Webcast - VERA THERAPEUTICS INC

Explicit Guidance:

• Regulatory Submission: Supplemental BLA to be submitted "this quarter" (Q4 2023) to support full approval of Atacicept (TruTacna).
• Approval Timeline: Anticipation of FDA review leading to full approval and an updated label in the "middle of 2027."
• Commercial Updates: Next quarterly earnings update and commercial traction report scheduled for "November."

Business-Segment Outlook:

• Atacicept (IgAN): Launch in the US for IgA nephropathy (IgAN) is currently "going well" under accelerated approval; commercial detailing is restricted to current label but is expected to "unlock" and inflect significantly following full approval in 2027.
• Pediatric/Adolescent Pipeline: Additional data on Atacicept for adolescents with IgAN to be presented at ASN; full results expected.
• Adjacent Indications: First data on Atacicept for membranous nephropathy (an adjacent autoantibody-driven kidney disease) to be presented Saturday afternoon at ASN.
• Commercial Expansion: Commercial sales force capability to be fully enabled to promote comprehensive data (GFR slope, avoidance of dialysis/transplant) upon full label update in 2027.

Market and Competitive Outlook:

• Competitive Landscape: Validation of the dual BAF/APRIL inhibition mechanism via two independent Phase 3 trials (Vera's Origin 3 and a separate competitor trial) targeting the same pathway; data validated "to the decimal point."
• Therapeutic Shift: Expectation of a "paradigm shift" from supportive care/steroids to precise immune modulation; steroids projected to be "in the history books" for IgAN treatment due to toxicity and inferior efficacy compared to Atacicept.
• Standard of Care: KDGO guidelines promoted "no wait and see" approach; immediate simultaneous therapy recommended for patients with >0.5g/day proteinuria, combining disease-modifying agents (TruTacna) with CKD management (RASi/SGLT2).
• Market Penetration: Anticipated increase in kidney biopsies and earlier diagnosis of IgAN (currently estimated 160k-300k US cases) due to industry awareness campaigns regarding genetic risk and earlier intervention.

Macro / Industry Outlook:

• Regulatory Trend: FDA and global regulators shifting toward 52-week GFR endpoints for IgAN approvals, moving away from longer-duration (104-week) or surrogate-only endpoints; Vera has "trailblazed" this 52-week GFR approach.
• Clinical Trial Design: Future pivotal trials in this space expected to utilize 52-week GFR endpoints (plus/minus proteinuria) for efficacy assessment, contingent on demonstrating transformative efficacy similar to Atacicept.
• Disease Burden: Recognition of high-risk patient populations where supportive care results in a 10% annual loss of kidney function; industry focus shifting to upstream pathophysiology targeting (B-cell/plasma cell dysregulation).

Strategic Initiatives:

• Dose Optimization: Ongoing dose range/frequency study for Atacicept evaluating three separate monthly dosing regimens; data expected "this quarter" to determine if less frequent dosing (e.g., every other week) is viable.
• Trial Integrity Protection: Strategic decision in Origin 3 to convert placebo patients to open-label active therapy after 52 weeks to protect patient health, resulting in a 3x higher discontinuation rate in the placebo arm due to kidney function loss.
• Open-Label Extension: All Origin 3 participants transitioning to open-label Atacicept; continued data collection planned through week 156 to assess long-term efficacy and safety.
• M&A/Partnership Context: No specific M&A mentioned; focus remains on internal commercialization and regulatory approvals.

Risks and Headwinds to Outlook:

• Regulatory Uncertainty: Full approval and expanded labeling (including composite endpoints, dialysis prevention) are anticipated only in 2027; current commercial use is restricted to accelerated approval based on proteinuria surrogate endpoints.
• Clinical Monitoring: Continued need for long-term follow-up on anti-drug antibodies (ADAs) and safety profiles, though currently deemed "no clinical relevance."
• Adoption Friction: Resistance from nephrologists to discontinuing established RAS inhibitor/SGLT2 therapy in favor of Atacicept monotherapy; industry must educate providers on "simultaneous therapy" rather than switching.
• Competitive Timing: Competitor drugs (e.g., Semaglutide, Teletacicept) are in development; differentiation relies on the specific safety profile and magnitude of GFR preservation.
• Market Education: Success dependent on raising awareness among primary care/urologists to increase biopsy rates and earlier diagnosis, as current diagnosis is often delayed until significant kidney damage (Stage 3 CKD) has occurred.

Management Tone on the Future:

• Confidence Level: High confidence in the data quality and mechanism; described results as "astounding," "outstanding," and a "paradigm shift."
• Strategic Pivot: Firm belief that Atacicept represents a "comprehensive disease modification" rather than just symptom management, capable of returning GFR loss to physiological rates (<1 ml/min/year).
• Forward-Looking Hedges: Acknowledges that long-term data (30-40 years of treatment) is still needed to fully understand lifetime efficacy, but current 2-year data supports immediate use.
• Commercial Sentiment: Expects a "nice inflection point" in uptake post-full approval, driven by the release of comprehensive efficacy data and the ability to detail on GFR benefits rather than just proteinuria.

Miscellaneous:

• Patient-Centric Trial Design: Origin 3 modified to end at week 52 for the primary GFR endpoint to prevent exposing placebo patients to rapid kidney function loss, a move endorsed by the FDA.
• Safety Profile: No deaths, dialysis-dependent failure, or kidney transplants occurred in the Atacicept group; serious adverse events lower in Atacicept vs. placebo; no clinically meaningful impact of ADAs.
• Subgroup Consistency: Treatment effect was identical across all pre-specified subgroups (age, gender, region, baseline GFR, SGLT2 use), with no identified subgroup showing reduced efficacy.